We thank Moneim and colleagues for calling attention to the issue of gender inequality in MS clinical trial steering committees and in authorship on publications emerging from phase 3 clinical trials.[1](#ana25359-bib-0001){ref-type="ref"} Gender inequality is a long‐standing problem in publication practices in general,[2](#ana25359-bib-0002){ref-type="ref"} as well as in neurology,[3](#ana25359-bib-0003){ref-type="ref"}, [4](#ana25359-bib-0004){ref-type="ref"} academic medicine,[5](#ana25359-bib-0005){ref-type="ref"} and science,[6](#ana25359-bib-0006){ref-type="ref"} so it is not surprising to see it reflected in the field of multiple sclerosis (MS). This occurs despite the availability of a substantial number of successful senior female academic neurologists and neuroscientists worldwide who have extensive experience in MS clinical and basic research methodology; some are cosigners of this letter. Are there additional reasons beyond those articulated by Moneim and colleagues to explain why senior female neurologists are not approached to play lead roles in MS clinical trial committees and more broadly, clinical MS neurologists and MS researchers?

Moneim and colleagues observed that women have been historically underrepresented as first and last authors on publications from phase 3 clinical trials in MS sponsored by pharmaceutical companies, which tend to repeatedly choose a select group of academicians to serve as authors.[7](#ana25359-bib-0007){ref-type="ref"} In addition, eminent lead investigators have to some extent, consciously or subconsciously, nurtured a closed group for clinical trial leadership in which women are not well represented. Publication practices may also be influenced by gender balance on journal editorial boards. In an informal examination of chief and section editors of 17 major journals that publish MS studies, we found that median representation by women was 16.6%. This is approximately half of the proportion of female faculty in the 29 top‐ranked US academic neurology programs (30.8%).[4](#ana25359-bib-0004){ref-type="ref"} Gender imbalance also occurs in scientific programs at professional meetings[8](#ana25359-bib-0008){ref-type="ref"} and in recognition awards,[9](#ana25359-bib-0009){ref-type="ref"} issues that have been addressed with limited success by the American Neurological Association, American Academy of Neurology, and the American and European Committees for Treatment and Research in MS.

Gender discrimination is costly, not only from a personal career perspective, but because it excludes or delays important contributions from skilled, talented individuals. This can affect progress toward a better understanding of the pathogenesis and treatment of neurological diseases, including MS.

Although it is disheartening to see continuing evidence of the gender discrimination that permeates not only academic medicine and science, but also society at large, we are encouraged that there is interest in shedding greater light on the issue. We believe that it is time for the MS community to work harder toward achieving equal participation by all women at all levels. To this end, we submit this letter as a call to action, and offer the following recommendations:Develop structured opportunities to foster greater awareness of gender‐based imbalances and existing biases, including implicit or unconscious bias. This can occur on a committee level in professional organizations and should include representatives from pharmaceutical companies. The primary goal would be to establish task forces charged with gathering and analyzing data on gender concerning:aClinical trial leadership, including clinical trial steering committees, data safety monitoring boards, authorship committees, and other active committees.bParticipation by physicians and basic scientists on editorial boards and grant review panels and in scientific programs, professional organizations, and academic institutions, including neurology departments, as well as in other relevant entities.Establish specific goals toward achieving equal representation by women at all levels in a timely fashion.aDevelop mechanisms to track and regularly review progress toward these goals, with an ultimate goal of achieving and maintaining gender parity.bCreate mechanisms to report inequalities and encourage continued efforts to raise awareness.cDevelop mechanisms to recognize and celebrate contributions from women.dPromote efforts to support and mentor women (such as the International Women in MS, the Women Leading in Neurology leadership program of the American Academy of Neurology,[3](#ana25359-bib-0003){ref-type="ref"} and the Association for Women in Science), especially for junior investigators.

There are many models and transformative voices[3](#ana25359-bib-0003){ref-type="ref"}, [6](#ana25359-bib-0006){ref-type="ref"}, [10](#ana25359-bib-0010){ref-type="ref"}, [11](#ana25359-bib-0011){ref-type="ref"}, [12](#ana25359-bib-0012){ref-type="ref"} that can be tapped in efforts to swing the pendulum toward a truly equal opportunity environment in the MS community. It is clear that conscious, thoughtful, and persistent efforts by all stakeholders, both men and women, are needed to implement enduring change worthy of celebration. We look forward to participating in an ongoing and collaborative dialogue toward achieving this important goal.
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